Udenyca (pegfilgrastim-cbqv) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

		L	
MEMBER INFORMATION			
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID I	NUMBER:		
MALE FEMALE	HEIGHT (IN/CM): WE	EIGHT (LB/KG): ALLERGIES:	
		DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND A	T THE
OLLOWING LINK: <u>PRIMETHERAPEUTICS.</u>	.COM/NOPP		
PATIENT'S AUTHORIZED R	EPRESENTATIVE (IF APPLICAB	ELE):	
AUTHORIZED REPRESENTA	ATIVE'S PHONE NUMBER:		
PRESCRIBER INFORMATION	ON		
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:			
STREET ADDRESS: CITY:		STATE: ZIP CODE:	
	rescriber):	STATE: ZIP CODE: OFFICE CONTACT PERSON:	
CITY:	rescriber):		
CITY: REQUESTOR (if different than p	orescriber): CAL DISPENSING INFORMATION	OFFICE CONTACT PERSON:	
CITY: REQUESTOR (if different than p		OFFICE CONTACT PERSON:	
CITY: REQUESTOR (if different than p		OFFICE CONTACT PERSON:	
CITY: REQUESTOR (if different than p MEDICATION OR MEDIC MEDICATION NAME: DOSE/STRENGTH:	FREQUENCY:	OFFICE CONTACT PERSON: N LENGTH OF QUANTITY: THERAPY/REFILLS:	
CITY: REQUESTOR (if different than p MEDICATION OR MEDIC MEDICATION NAME:	FREQUENCY:	OFFICE CONTACT PERSON: N LENGTH OF QUANTITY:	

Continued on next page.



Udenyca (pegfilgrastim-cbqv) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTH	ER MEDICATIONS FOR THIS CONDITION	? YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Febrile neutropenia prevention	uta Dadiatia a Cuadana	
☐ Hematopoietic Subsyndrome of Act	ute Radiation Syndrome	
□ Other diagnosis:	_ICD10	
	N: PLEASE PROVIDE ALL RELEVANT CLINI	CAL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.		
Is the prescribed medication being u	sed to prevent febrile neutropenia in a	previously untreated adult or pediatric
patient? 🗆 Yes 🗆 No		
Does the nationt have a diagnosis of	a non-myeloid malignancy and is the p	ationt receiving shometherapy and for
	ence of febrile neutropenia of 20% or gr	• • • • • • • • • • • • • • • • • • • •
, , , , , , , , , , , , , , , , , , , ,	.	
Is the patient at an increased risk for reasons?*	developing chemotherapy-induced info	ections due to any of the following
☐ Pre-existing neutropenia (ANC of	1.000/mm³ or less)	
☐ Extensive prior exposure to chem	-	
·	her areas of large amounts of bone mar	row to radiation
·	-	Tow to radiation
☐ History of recurrent febrile neutro		
□ Patient is 65 years of age or older		
☐ Patient has a condition that can p	ootentially increase the risk of serious in	fectin(I.e., HIV/AIDs)
*Please submit documentation.		
Are there any other comments, diag physician feels is important to this re		failed, and/or any other information the
Please note: Not all drugs/diagnosis a information is received.	are covered on all plans. This request ma	y be denied unless all required



Udenyca (pegfilgrastim-cbqv) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic I.D. Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confide you are not the intended recipient, you are hereby notified that any disclosure, copying, dis of these documents is strictly prohibited. If you have received this information in error, pleased arrange for the return or doctruction of these documents.	stribution, or action taken in reliance on the contents			

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

